Guy Young, MD

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed mitigation strategies in trials and clinic.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed improving outcomes in hemophilia with fitusiran.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH study of fitusiran.